Literature DB >> 14615712

Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes.

Susan D Horn1, Randall J Smout.   

Abstract

OBJECTIVES: To determine if gestational age (GA) is independently associated with hospital resource use and outcomes among infants hospitalized for respiratory syncytial virus (RSV). STUDY
DESIGN: Analysis of retrospective data from 304 infants (</=1 year) with bronchiolitis or RSV pneumonia admitted to nine children's hospitals from April 1995 to September 1996. Resource use and outcomes examined included admission to the intensive care unit (ICU), intubation, and hospital and ICU length of stay. The Comprehensive Severity Index controlled for severity of illness.
RESULTS: Two hundred fifteen term infants (GA > or =37 weeks) and 89 infants with GA <37 weeks, divided according to GA into 3 subgroups (< or =32, 33 to 35, and 36 weeks), were compared. Significant differences were found for rate of intubation (P=.002) and ICU and hospital length of stay (P=.021 and P<.0001, respectively), with the highest resource use in 33 to 35 weeks GA infants, which remained significant in multiple regression analyses.
CONCLUSIONS: Infants 33 to 35 weeks GA had hospital outcomes that were negative or worse than infants < or =32 weeks GA. Data suggest prematurity < or =35 weeks GA significantly increases the risk for severe outcomes among infants hospitalized for RSV. Infants 36 weeks GA had outcomes similar to term infants. No evidence was observed of gradation or inverse linear risk relation between GA and hospital outcomes.

Entities:  

Mesh:

Year:  2003        PMID: 14615712     DOI: 10.1067/s0022-3476(03)00509-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  38 in total

Review 1.  Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

Authors:  Andrew A Colin; Cynthia McEvoy; Robert G Castile
Journal:  Pediatrics       Date:  2010-06-07       Impact factor: 7.124

2.  Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

3.  Elevated Levels of Type 2 Respiratory Innate Lymphoid Cells in Human Infants with Severe Respiratory Syncytial Virus Bronchiolitis.

Authors:  Luan D Vu; David Siefker; Tamekia L Jones; Dahui You; Ryleigh Taylor; John DeVincenzo; Stephania A Cormier
Journal:  Am J Respir Crit Care Med       Date:  2019-12-01       Impact factor: 21.405

4.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

5.  RSV infection among children born moderately preterm in a community-based cohort.

Authors:  Rolof G P Gijtenbeek; Jorien M Kerstjens; Sijmen A Reijneveld; Eric J Duiverman; Arend F Bos; Elianne J L E Vrijlandt
Journal:  Eur J Pediatr       Date:  2014-09-06       Impact factor: 3.183

6.  The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.

Authors:  Michelle L Butt; Amanda Symington; Marianne Janes; Louann Elliott; Susan Steele; Bosco A Paes
Journal:  Eur J Pediatr       Date:  2010-12-22       Impact factor: 3.183

7.  Preterm cord blood CD4⁺ T cells exhibit increased IL-6 production in chorioamnionitis and decreased CD4⁺ T cells in bronchopulmonary dysplasia.

Authors:  Ravi Misra; Syed Shah; Deborah Fowell; Hongyue Wang; Kristin Scheible; Sara Misra; Heidie Huyck; Claire Wyman; Rita M Ryan; Anne Marie Reynolds; Tom Mariani; Philip J Katzman; Gloria S Pryhuber
Journal:  Hum Immunol       Date:  2015-03-20       Impact factor: 2.850

8.  A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-01       Impact factor: 3.267

9.  A Review of the CD4+ T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population.

Authors:  Ravi S Misra
Journal:  EC Microbiol       Date:  2014

Review 10.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.